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Abstract
Introduction and methods: In order to verify whether parvalbumin (PVALB),
a protein specifically expressed by GABAergic interneurons, could be a MS-
specific marker of grey matter neurodegeneration, we performed neuropathol-
ogy/molecular analysis of PVALB expression in motor cortex of 40 post-mor-
tem progressive MS cases, with/without meningeal inflammation, and 10
control cases, in combination with cerebrospinal fluid (CSF) assessment. Analy-
sis of CSF PVALB and neurofilaments (Nf-L) levels combined with physical/
cognitive/3TMRI assessment was performed in 110 na€ıve MS patients and in 32
controls at time of diagnosis. Results: PVALB gene expression was downregu-
lated in MS (fold change = 3.7  1.2, P < 0.001 compared to controls) reflect-
ing the significant reduction of PVALB+ cell density in cortical lesions, to a
greater extent in MS patients with high meningeal inflammation (51.8,
P < 0.001). Likewise, post-mortem CSF-PVALB levels were higher in MS com-
pared to controls (fold change = 196  36, P < 0.001) and correlated with
decreased PVALB+ cell density (r = 0.64, P < 0.001) and increased MHC-II+
microglia density (r = 0.74, P < 0.01), as well as with early age of onset
(r = 0.69, P < 0.05), shorter time to wheelchair (r = 0.49, P < 0.05) and
early age of death (r = 0.65, P < 0.01). Increased CSF-PVALB levels were
detected in MS patients at diagnosis compared to controls (P = 0.002). Signifi-
cant correlation was found between CSF-PVALB levels and cortical lesion num-
ber on MRI (R = 0.28, P = 0.006) and global cortical thickness (R = 0.46,
P < 0.001), better than Nf-L levels. CSF-PVALB levels increased in MS patients
with severe cognitive impairment (mean  SEM:25.2  7.5 ng/mL) compared
to both cognitively normal (10.9  2.4, P = 0.049) and mild cognitive impaired
(10.1  2.9, P = 0.024) patients. Conclusions: CSF-PVALB levels reflect loss of
cortical interneurons in MS patients with more severe disease course and might
represent an early, new MS-specific biomarker of cortical neurodegeneration,
atrophy, and cognitive decline.
Introduction
Multiple Sclerosis (MS) is the commonest inflammatory
neurodegenerative disorder of the human central
nervous system (CNS), characterized histologically by
multifocal areas of inflammation, demyelination, and
neurodegeneration1,2 within the white matter3 (WM), but
also within cortical and deep grey matter4 (GM). GM
pathology is present in the MS brain since the earliest
stages of the disease5,6 and accumulates, in particular, in
the progressive phase,7,8 contributing to the increase in
physical disability9,10 and cognitive impairment.11,12
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Brain-imaging studies have confirmed that cortical thin-
ning occurs prominently in areas of the brain that have
extensive cortico-cortico connections, such as the cingu-
late gyrus, insula and superior frontal gyrus, while, pri-
mary sensory and visual areas are less significantly
involved.13 A “surface-in” gradient of neuronal loss has
been identified in the motor cortex of post-mortem MS
cases with elevated meningeal inflammation characterized
by the presence of lymphoid-like structures and a more
aggressive disease course.14,15 Cortical neuronal vulnera-
bility and damage in the upper cortical layers, including
both dysfunction and loss, is now thought to be a major
contributor to the progression of MS,16–18 independently
from cortical demyelination. However, following the pro-
gression of neurodegeneration in vivo has so far proven
elusive.
Recent evidence has confirmed an association between
CSF inflammatory protein profile, meningeal inflammation
and GM damage, as visualized with advanced MRI tech-
niques.19,20 In addition, proinflammatory cytokines/
chemokines together with neurofilament proteins are sug-
gested to be useful biomarkers of cortical pathology and
neurodegeneration in MS.20 Neurofilament light chain (Nf-
L) is a cytoskeletal component of neurons, particularly
abundant in axons, that is released into the extracellular
space following axonal destruction and then drains into
the CSF, thus providing an indication of axonal damage
and neuronal death. Nf-L levels are increased in the CSF
of MS patients who convert earlier to secondary progres-
sion.21 However, increased CSF levels of Nf-L occur in all
neurodegenerative conditions, including stroke,22 amy-
otrophic lateral sclerosis,23 and frontotemporal dementia.24
We recently reported a substantial reduction in PVALB
gene expression in both demyelinated and nondemyeli-
nated regions of the motor cortex of post-mortem sec-
ondary progressive MS (SPMS) brains, which reflected the
degree of meningeal inflammation and cortical neurode-
generation, whereas the reduction in expression of the Nf-
L gene did not reflect these pathologies.25 This suggests
that changes in PVALB protein levels in the CSF might
give a more accurate and specific indication of the degree
of ongoing cortical neurodegeneration than Nf-L.
PVALB is a calcium binding protein expressed in a
subset of GABA-ergic inhibitory cortical interneurons and
PVALB expressing cells have been classified as fast-spiking
interneurons.26 PVALB is known to buffer calcium ion
levels and has been shown to protect neurons from excess
intracellular calcium.27,28 Previous observations in MS
showed a decrease in GABA-ergic PVALB+ interneurons
in layer II of the primary motor cortex of MS patients, in
particular within the NAGM.29,30 Furthermore, a signifi-
cant correlation between numbers of PVALB expressing
cells and age at death was found, suggesting a possible
association between MS disease duration and loss of
PVALB interneurons.30 Our previous data showing
decreased PVALB gene expression in MS cases with a
more rapid and severe disease progression and increased
cortical pathology25 suggests the possibility of using
PVALB protein levels as a biomarker for cortical GM
neurodegeneration to identify at an early stage those indi-
viduals at risk of a more severe and rapid MS disease pro-
gression.
In the present study, we investigated the extent of
PVALB+ cell loss in cortical lesions in the motor cortex
of post-mortem MS cases compared to control cases and
measured PVALB protein levels in paired CSF samples.
Moreover, we conducted a combined in-vivo CSF and
3T-MRI analysis, together with clinical and neuropsycho-
logical assessments, in a cohort of MS patients at the time
of diagnosis, in order to evaluate if PVALB may represent
a specific biomarker associated with cortical neurodegen-




Post-mortem MS and control tissues
All post-mortem tissues were obtained from the UK MS
Society Tissue Bank at Imperial College London (London,
UK) and were obtained at autopsy with fully informed
consent under ethical approval by the National Research
Ethics Committee (08/MRE09/31), with the exception of
three controls provided by University of Verona (Verona,
Italy). Demographic/clinical/ neuropathological character-
istics of the SPMS cases and controls are shown in
Table 1. The clinical diagnosis of SPMS (median post-
mortem delay = 14.4 h) was confirmed based on the
patient medical history and a detailed neuropathological
analysis as described previously.1 The neuropathological
study was performed on two independent groups of post-
mortem SPMS cases: (1) precentral gyrus snap frozen tis-
sue blocks from a cohort of 20 post-mortem cases of
SPMS previously characterized for the presence (n = 10,
FposSPMS) or absence (n = 10, FnegSPMS) of tertiary
lymphoid-like tissues in the leptomeninges14; (2) precen-
tral gyrus paraffin tissue blocks from an independent
cohort of 20 post-mortem cases of SPMS previously char-
acterized for the presence of elevated (10 MShigh) or low
(10 MSlow) levels of meningeal inflammation.20 In addi-
tion, 13 non-neurological control cases (median post-
mortem delay = 12 h; median age at death = 58 years)
have been also analyzed.
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Gene expression analysis
Gene ontology (GO) analyses were performed using
DAVID Bioinformatics resources (6.8) on Illumina whole
genome HumanRef8 v2 BeadChip expression array data,
from grey matter tissue dissected from the precentral
gyrus snap frozen tissue blocks, that was previously
described and reported,25 Protein–protein interaction
(PPI) analysis was performed by using STRING software
(version 11.0) and Cytoscape software (version 3.7.1) was
used to visualize the PPI analysis.
Immunohistochemistry and analysis
Quantitative analysis of the distribution and density of
PVALB+ neurons was performed by counting PVALB+
cells on both sections cut from the snap frozen precentral
gyrus blocks of the first cohort and on sections of forma-
lin fixed paraffin embedded (FFPE) precentral gyrus
blocks of the second cohort, in comparison with to the
respective control cases. PVALB+ cells were identified by
immunohistochemical localization of PVALB protein
expression using a rabbit anti-PVALB antibody (SWANT,
Rte Ancienne Papeterie, Switzerland). Double immuno-
histochemistry with mouse anti-NeuN antibody (Chemi-
con International, Temecula, CA) was performed in order
to confirm the expression of PVALB on neurons (Fig. 1).
Briefly, snap frozen sections and dewaxed paraffin sec-
tions from precentral gyrus were dehydrated and
immunostained with myelin oligodendrocyte (MOG),
major histocompatibility class II (MHC class-II) and
PVALB detecting antibodies following the immunohisto-
chemistry procedures previously described15,31). Antibody
binding was visualized using peroxidase or alkaline phos-
phatase systems (Vector Labs, Peterborough, UK) and
images were acquired with Axiophot (ZEISS) microscope.
For each case of the two MS cohorts and of control
group, four random fields (209 objective) were acquired
in type III cortical lesions and NAGM, by considering a
central rectangular grid (0.032 mm2) drawn in each
acquired field to avoid the simultaneous analysis of adja-
cent layers. Results were expressed as cell density/mm2.
The 4 adjacent fields were acquired from the pial surface
toward the WM, covering all the 6 cortical grey matter
layers in order to assess the density of all the PVALB+
neurons and to avoid any bias due to the layer to layer
variation. The counts were performed blinded (RM) with
respect to the disease/control condition on three consecu-
tive sections immunostained with PVALB antibody for
each examined case and the means and standard errors
were calculated. Both manual and automatic (QuPath
Analysis) methods were tested and were almost com-
pletely comparable, but the manual count was finally
selected as it helped exclude any nonspecific objects.
CSF post-mortem analysis
The PVALB levels were measured in duplicate in the
available CSF samples available from the second MS

















3 M 34 46 21 55
42 M 29 46 22 51
56 M 24 39 39 63
74 F 28 50 36 64
100 M 37 38 9 46
104 M 41 46 12 53
114 F 37 39 15 52
127 M 28 44 24 52
163 F 39 41 6 45
200 M 19 28 24 43
Fpos MS
MS79 F 25 35 24 49
MS92 F 20 28 18 38
121* F 35 36 35 35
124 F 24 26 24 24
180* F 25 26 25 25
197* F 24 46 27 51
230* F 22 35 22 22
234* F 24 31 15 39
256* F 29 38 24 53
286* M 29 34 29 29
II Group
MS-Low
296 M 19 48 40 59
301 F 21 36 41 62
304 M 29 37 23 52
318 F 25 46 34 59
347 M 22 47 28 50
364 F 22 32 34 56
422 M No data No data 58 58
444 M 28 31 21 49
461 M 23 32 20 43
485 F 27 50 57 57
MS-High
407 F 25 33 19 44
MS402 M 25 37 21 46
MS408 M 28 36 11 39
MS423 F 24 33 30 54
MS438 F 17 49 36 53
MS473 F 9 32 31 40
MS497 F 45 47 15 60
MS510 F 16 23 22 38
MS513 M 33 40 18 51
MS527 M 21 33 25 46
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group (Table 1) using a Human Parvalbumin ELISA kit
(MBS2022353, MyBioSource, San Diego, CA, USA)
according to the manufacturer’s instructions. Briefly, the
precoated wells were incubated with 100 lL of a 1:1 dilu-
tion of the post-mortem CSF for 2 h at 37°C and then
incubated with reagent A for 1 h at 37°C. After washing
the samples were incubated with reagent B at 37°C for
30 min and incubated with TBM ELISA substrate at 37°C
after washing. The reaction was stopped after 20 min with
a specific solution and the optical density was measured
at 450 nm on a Model 680 Series microplate reader (Bio-
Rad). Samples were analyzed in random order and staff
were blinded to the treatment arms. The detection thresh-
old was of 0.55 ng/mL. Intra-assay variability (coefficients
of variation) of the samples was below 10%. The levels of
neurofilament protein light chain (Nf-L) in post-mortem
CSF samples were measured using a Human Nf-L ELISA
kit (MyBioSource, San Diego, CA, USA) according to
previously optimized procedures20 and the quantification
was carried out on a VICTOR X3 2030 Multilabel
Plate Reader (Model 680 Series microplate reader, Bio-
Rad) with a detection threshold of 0.06 ng/mL (Perkin
Elmer, Walluf, Germany). Intra-assay variability (coeffi-
cients of variation) of the samples was below 10%.
Clinical study
In vivo patient cohort
One hundred and ten treatment na€ıve MS patients
(76 females, age = 38.4  2.4 years, disease dura-
tion = 2.8  4.5 years) were enrolled at the time of diag-
nosis at the MS Centre of the Verona University Hospital.
Patients underwent a CSF withdrawal by lumbar punc-
ture, a neurological evaluation including the measure of
the Expanded Disability Status Scale (EDSS)32 (median
EDSS = 2, range 0–4), a 3T MRI scan, and a neuropsy-
chological assessment. The study was approved by the
Ethics Committee of the University of Verona and
informed consent was collected from all participants
(MSBioB Biological bank – A.O.U.I, Verona; Protocol
number 66418, 25/11/2019).
CSF analysis
CSF levels of PVALB and Nf-L were measured using a
Parvalbumin ELISA kit (MBS2022353, MyBioSource) and
Human Nf-L ELISA kit (MyBioSource,), respectively, as
described above. PVALB and Nf-L levels were also evalu-
ated in the CSF of 32 control subjects (Suppl. Materials).
MRI acquisition and analysis
Three tesla MRI was performed at the Radiology unit of
the Verona University Hospital (Italy) by using a Philips
Achieva 3T MR Scanner. The acquisition protocol con-
sisted of: (1) a 3D T1 weighted Turbo Field Echo (TFE)
(Repetition Time (TR) / Echo Time (TE) = 8.4/3.7 msec,
voxel size of 1 9 1 9 1 mm), total acquisition time of
5:51 min; (2) a 3D Double Inversion Recovery (DIR)
(TR/TE = 5500/292 msec, Inversion Times (TI) TI1/
TI2 = 525/2530 msec voxel size of 1 9 1 9 1 mm),
Turbo Spin Echo (TSE) readout, number of excitations 3,
acquisition time of 10:49 min; (3) a 3D Fluid Attenuated
Inversion Recovery (FLAIR) (TR/TE = 8000/292 msec,
TI = 2350 msec voxel size of 1 9 1 9 1 mm), same TSE
readout as the DIR sequence, number of excitations 1,
acquisition time of 4:50 min. The acquired images were
analyzed to assess the lesion load both in white and grey
matter. WM lesions were identified and segmented on
FLAIR images using a semiautomatic lesion segmentation
technique included in MIPAV (Medical Image Processing
and Visualization; mipav.cit.nih.gov) software. The num-
ber of cortical lesions (CLs) was assessed on DIR images
following the recent recommendations for cortical lesions
scoring in patients with MS.33 Owing to the suboptimal
performance of the image-acquisition sequences on MRI
in visualizing subpial lesions, the present analysis has
taken into account mainly the intracortical and leukocor-
tical lesions. Global and regional cortical thickness evalua-
tion was performed on the 3D T1w scan by using the
Freesurfer image analysis suite, available online (http://
surfer.nmr.mgh.harvard.edu/), as previously described.34
All images were accurately controlled for errors/artefacts
by an experienced neurologist (MC) and defects due to
tissue lesions were corrected using a semi-automated pro-
cedure involving lesions filling.
Neuropsychological assessment
Neuropsychological assessment was available in a sub-
group of 93 out of 110 MS patients (85% of the whole
sample). The battery of neuropsychological tests was com-
posed of the Brief Repeatable Battery35 (BRB;) and the
Stroop Test36 (ST). Scores below the cut-off (5th per-
centile) of the reference population of each test were clas-
sified as failed test. MS patients were classified as being
cognitively normal (CN, 0 failed subtest) or as having
mild cognitive impairment (mCI, up to two failed sub-
tests) or severe cognitive impairment (sCI, at least three
failed subtests) considering their performance on all neu-
ropsychological tests administered (for the same proce-
dure, see Pitteri et al., 2017).37
ª 2021 The Authors. Annals of Clinical and Translational Neurology published by Wiley Periodicals LLC on behalf of American Neurological Association 537
R. Magliozzi et al. Parvalbumin Biomarker of Multiple Sclerosis Neurodegeneration
538 ª 2021 The Authors. Annals of Clinical and Translational Neurology published by Wiley Periodicals LLC on behalf of American Neurological Association
Parvalbumin Biomarker of Multiple Sclerosis Neurodegeneration R. Magliozzi et al.
Statistical analysis
Statistical analyses were performed using GraphPad Prism
5 software (GraphPad, La Jolla, CA, USA), R (https://www.
r-project.org/, version 3.3), and SPSS statistic (SPSS Inc,
Chicago, Illinois, USA, version 24) programs. R, Cytoscape
(version 3.7.1) and Inkscape (version 0.92.4) were used to
draw graphs. For bioinformatic analyses, modified Fisher’s
exact P value (EASE) was used to determine the gene-en-
richment analysis and Benjamini-Hochberg multiple test
correction to calculate the false discovery rate (FDR).
Shapiro–Wilk test was used to assess the data distribution.
Difference between groups were evaluated performing
Mann–Whitney test and one-way analysis of variance (one-
way ANOVA) followed by post-hoc Tukey test.
Pairwise univariate Spearman rank index was used to
evaluating the association between demographical, clini-
cal, neuroradiological, neuropsychological parameters and
the CSF PVALB/Nf-L. We tested multiple regression anal-
yses to find which CSF-biomarkers among PVALB and
Nf-L better explained each neuroimaging feature.
Collinearity was checked by Variance Inflation Factors.
Regression diagnostic was used in order to explore the
model’s statistical assumptions: homoscedasticity and nor-
mality of residuals visual inspections did not show impor-
tant deviations. CSF levels were log transformed to
approximate a normal distribution as well as to obtain
reliable Beta estimates.
A hierarchical regression model was performed to bet-
ter explain the amount variance of mean global CTh
combining CSF PVALB and CSF Nf-L.
Correlations between CSF PVALB/Nf-L levels and
PVALB+ cell counts, % GM demyelination, MHC-II+ cell
counts were evaluated using pairwise univariate Pearson
coefficient. A false discovery rate (FDR) correction was
applied. Unless otherwise indicated, mean  SEM was
provided for post-mortem data considering the smaller
sample, while mean  SD was provided for in-vivo data.
A P-value less than 0.05 was considered significant.
Results
Post-mortem tissue study
Downregulation of PVALB gene in MS reflects
reduction of PVALB+ cells in post-mortem tissue
of MS brains
We selected the most de-regulated genes expressed in GM
lesions of the motor cortex derived from Fpos SPMS
(GML_Fpos) cases respect to controls (Fold Change > 2,
P < 0.01; Fig. S1A and B) from our previously reported
gene expression dataset25 and performed gene ontology
enrichment analyses. Most of the selected genes are local-
ized in neurons and involved in neuron-associated biolog-
ical processes (Fig. 1A) and molecular functions
(Fig. 1B), such as neuron differentiation and voltage-
gated ion channel activity. Accordingly, the most enriched
cellular component clusters were related to neuronal pro-
cesses such as axons and neuron projections (Fig. S1A).
Protein-protein interaction analysis revealed a core net-
work particularly enriched in “neuron part” cluster
(Fig. S1E). The expression of these neuronal genes was
investigated in our three other datasets (NAGM_FPOS:
normal appearing GM in follicle-positive SPMS cases;
GML_Fneg: GM lesions in follicle-negative SPMS cases;
NAGM_Fneg: normal appearing GM in follicle-negative
SPMS cases).25 PVALB was the most downregulated gene
(fold change = 3.7  1.2, P < 0.00) in both GML and
NAGM of Fpos cases, whereas Fneg cases showed a very
different overall expression pattern for the genes of inter-
est (Fig. S1B).
PVALB expressing interneuron numbers are
substantially reduced in MS cortex
Quantitative analysis of the density of PVALB+ cells
(Fig. 1E) in the motor cortex of the control (Fig. 1C) and
MS (Fig. 1D) cases, revealed a significant (P < 0.0001)
Figure 1. Molecular and neuropathology analysis of PVALB expression in post-mortem progressive MS. Gene ontology enrichment analysis for
the top five biological process (A) and molecular function (B) clusters of differentially expressed genes in post-mortem precentral gyrus with grey
matter (GM) lesions derived from SPMS cases characterized by the presence follicle-like structures (Fpos). A modified Fisher’s exact P-value (EASE)
was used to determine the gene-enrichment analysis and Benjamini–Hochberg multiple test correction was applied to calculate the False Discovery
Rate (FDR). Immunohistochemical assessment of PVALB+ cells in the precentral gyrus (motor cortex) of one post-mortem control (C) and one MS
case (D). PVALB immunostaining detected a subpopulation of cortical neurons (E). (F) Boxplot reporting the percentage reduction of PVALB+ cells
with respect to control in post-mortem precentral gyrus of the two independent MS cohorts (group I and II). (G) PVALB protein levels in available
paired CSF post-mortem samples (n = 20) and age-matched healthy controls (n = 10). (H) Nf-L protein levels in available paired CSF post-mortem
samples (n = 20) and age-matched healthy controls (n = 10). (I) Summary table of the correlation analyses between PVALB/Nf-L CSF levels and
PVALB+ cell counts, % GM demyelination, MHC-II+ cell counts, age of disease onset (years), age at wheelchair (years; EDSS = 7), disease duration
(years), and age at death (years). Means and SEM were used to represent the data. Dots represent the samples analyzed. *P < 0.05; **P < 0.01;
***P < 0.001. pm-MS: post-mortem Multiple Sclerosis cases; Ctrl: controls; R: correlation coefficient; P: P-value; GM: grey matter; MHC-II: major
histocompatibility complex-II. Original magnifications: A, B 1009; B, D 4009.
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reduction of PVALB+ cell density in follicle-positive
(Fpos) MS cases (51.6%) and follicle-negative (Fneg) MS
cases (25.3%) with respect to controls (Fig. 1F). In addi-
tion, PVALB+ cell density reduction was significantly
higher in Fpos respect to Fneg cases (Fig. 1F). Similarly, a
significant (P < 0.0001) reduction of PVALB+ cell density
was measured in the motor cortex of the second, inde-
pendent, post-mortem MS group, in both MShigh cases
(47.6%; P < 0.0001) and MSlow cases (31.5%;
P < 0.0001) with respect to controls (Fig. 1F). In addi-
tion, PVALB+ cell density reduction was significantly
higher in MShigh respect to MSlow cases (Fig. 1F).
PVALB protein levels are significantly elevated in
post-mortem CSF
Analysis of PVALB protein levels in the available paired
CSF samples of the post-mortem MS and control cases
demonstrated significantly higher levels in MS
(mean  SEM = 64.3  8.2; P < 0.0001) compared to
controls (mean  SEM = 0.32  0.06) (Fig. 1G). Simi-
larly, significantly increased CSF Nf-L levels were found
in MS (mean  SEM = 81.01  10.8; P < 0.0001) com-
pared to controls (mean  SEM = 0.34  0.07)
(Fig. 1H). There was a modest correlation between CSF
levels of PVALB and Nf-L (r = 0.38; P = 0.09).
When CSF PVALB and Nf-L levels were compared with
cell counts performed in the same MS cases, PVALB
levels correlated negatively with PVALB cell counts
(r = 0.64; P < 0.01) and positively with % of GM
demyelination (r = 0.66; P < 0.01) and numbers of acti-
vated microglia/macrophages (r = 0.74; P < 0.01)
examined in the same areas (Fig. 1I). There was also a
significant negative correlation between CSF PVALB levels
and age of onset (r = 0.46; P < 0.05), age at wheelchair
use (r = 0.50; P < 0.05) and age at death (r = 0.65;
P < 0.01), but not with disease duration (Fig. 1I). In con-
trast, a significant negative correlation was only found
between Nf-L CSF levels and age of onset (r = 0.46;
P < 0.05) (Fig. 1I).
Patient cohort study
CSF PVALB is increased in MS at the time of
diagnosis
Significantly increased PVALB levels were present in the
CSF of MS patients (fold change = 3.0  2.1, P = 0.002)
when compared to the control cohort (Fig. 2A). Likewise,
a significant increase of Nf-L levels was found in the CSF
of MS patients (fold change = 3.5  1.3, P < 0.001) com-
pared to controls (Fig. 2B). The levels of PVALB and Nf-
L in post-mortem CSF samples (PVALB mean  SEM
= 42.4 + 5.2; Nf-L mean  SEM = 81.0  6.4 ng/mL)
were substantially higher compared to those in
na€ıve MS patients at diagnosis, as expected (PVALB
mean  SD = 5.2  8.3 ng/mL; Nf-L median  SD
= 1.0  1.3 ng/mL). There was a significant positive cor-
relation between CSF levels of PVALB and Nf-L
(r = 0.36, P < 0.001) (Fig. 2C). On the contrary, no sig-
nificant correlation was found between PVALB (and Nf-
L) levels and age, disease duration, gender, and EDSS.
Moreover, no significant correlation was found between
EDSS and WM lesion number.
Figure 2. Increased CSF PVALB and Nf-L levels in MS patients. (A) PVALB protein concentration in CSF from controls (n = 32) and MS patients
(n = 110). (B) Nf-L protein concentration in CSF from controls (n = 32) and MS patients (n = 110). (C) Correlation between CSF PVALB and Nf-L
levels in MS patients (r = 0.036, P < 0.001, n = 110). Boxplots show the medians and the two hinges. Dots represent the samples analyzed.
*P < 0.05, ***P < 0.001. MS: Multiple Sclerosis; Ctrl: controls; r: Pearson correlation coefficient; P: P-value.
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Increased PVALB levels are associated with
cortical damage
The global CTh (mean  SD = 2.44  0.34 mm, range
1.42–3.00 mm) correlated moderately with CSF PVALB
levels (R = 0.46, P < 0.001) and only slightly with Nf-L
levels (R = 0.23, P = 0.024) (Fig. 3A, C and D and
Table S2). The global CTh was found to be associated
with CSF PVALB levels in a partial correlation controlling
for the number of CLs (r = 0.32, P = 0.001).
Furthermore, two nested regression models were
assessed using global CTh as dependent variable: the first
model (model-1) included only the CSF Nf-L variable
and in the next step (model-2) CSF PVALB was added.
Then, ANOVA analysis was applied to compare the two
models by Sum of Square (SS) and R2. Model-1 revealed
that CSF Nf-L was associated with the Global CTh
(b = 0.12, P = 0.005, R2 = 0.07) but by adding the CSF
PVALB the variance of Global CTh was explained only by
CSF PVALB (CSF PVALB b = 0.09, P < 0.001, CSF Nf-
L, P = 0.09 and R2 = 0.26). Model-2 accounts for addi-
tional SS = 2.3 and the R2 increased by 0.19 (P < 0.001).
Moreover, the number of CLs (mean  SD
= 3.88  5.00, range 0–23) was slightly correlated with
CSF PVALB levels (R = 0.28, P = 0.006) and with Nf-L
levels (R = 0.31, P = 0.003), whereas WM lesion number
(mean  SD = 8.79  3.99, range 0–19) did not
correlate with CSF levels of PVALB (Fig. 3B) or Nf-L.
Regression models confirmed these results. In fact, the
analysis revealed that unlike Nf-L levels, CSF PVALB
levels were associated with global CTh (b = 0.09,
P < 0.001). Also, both CSF PVALB and Nf-L levels were
related to the CL load (PVALB: b = 0.89, P = 0.001; Nf-
L: b = 2.26, P < 0.001). Finally, like univariate correlation
analysis, multivariate regression showed that neither CSF
PVALB nor Nf-L levels were linked to WM lesion
number.
Increased PVALB levels are associated with
fronto-temporal thinning
The regional analysis revealed that PVALB was signifi-
cantly associated with CTh of several brain regions
(Fig. 4A and Table 2); in particular, using both correla-
tion analysis and regression models, PVALB strongly cor-
related with the CTh of insula (correlation: R = 0.55,
P < 0.001; regression: b = 0.62, P < 0.001), cingulate
gyrus (R = 0.47, P < 0.001, b = 0.36, P < 0.05), hip-
pocampus (R = 0.46, P < 0.001, b = 0.31, P < 0.001),
post-central gyrus (R = 0.46, P < 0.001, b = 0.22,
P < 0.001), parahippocampal gyrus (R = 0.43,
P < 0.001, b = 0.30, P < 0.01), middle temporal gyrus
(R = 0.42, P < 0.001, b = 0.36, P < 0.01), and supe-
rior frontal gyrus (R = 0.42, P < 0.001, b = 0.22,
Figure 3. 3T MRI global outcomes correlations with CSF PVALB and Nf-L levels in MS patients. (A) Correlation plot showing different strength of
correlation between CSF PVALB and Nf-L levels with MRI parameters. A false discovery rate (FDR) correction was applied. The Spearman rank
index is proportional to the dimension/intensity of the bubbles. A color scale was used to determine the slope of the correlation. Blank squares
indicate no significant correlation. (B) Scatter plot of relationship between CSF PVALB levels and global cortical thickness (CTh) in MS patients. (C)
Scatter plot of relationship between CSF PVALB levels and number of cortical lesions (CLs) in MS patients. Dots represent the samples analyzed.
CLs: cortical lesions; CTh: cortical thickness; R: Spearman correlation coefficient; P: P-value.
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P < 0.001) (Fig. 4B–H). See Table 3 for multiple regres-
sion analysis. In contrast, only few significant correlations
were found between Nf-L levels and regional CTh levels
(Fig. 4A; Fig. S3).
CSF PVALB is increased in patients with severe
global cognitive impairment
Thirty-nine (42%) of the 93 MS patients who underwent
the neuropsychological assessment were classified as being
cognitively normal (CN), 39 (42%) as having mild cogni-
tive impairment (mCI), and 15 (16%) as having severe
cognitive impairment (sCI). PVALB levels were signifi-
cantly different among the three groups (P = 0.026):
post-hoc analyses showed no significant difference
between CN and mCI (P = 0.508) groups, while patients
with sCI were characterized by a significant increase of
PVALB levels (mean  SEM = 25.2  7.5 ng/mL)
compared to both CN (mean  SEM = 10.9  2.4 ng/
mL, P = 0.049) and mCI (mean  SEM = 10.1 
2.9 ng/mL, P = 0.024) patients (Fig. 5A). On the con-
trary, no significant difference was observed for
NF-L levels among the three subgroups (P = 0.220)
(Fig. 5B).
Discussion
In the present study, we investigated the extent of the loss
of PVALB+ GABAergic interneurons in the motor cortex
of post-mortem MS cases compared to controls and pro-
vided a possible link with increased PVALB levels in the
CSF from the same cases. Our data strongly suggest that
CSF protein levels of PVALB reflect loss of GABAergic
interneurons in MS cortex in progressive MS at the time
of death. By combining CSF and 3T-MRI analyses in a
cohort of MS patients at the time of diagnosis, together
Figure 4. CSF PVALB levels correlations with 3T-MRI regional CTh in MS patients. (A) Correlation plot chart showing the correlation between
PVALB levels and Nf-L with regional cortical thicknesses. A false discovery rate (FDR) correction was applied. The Spearman rank index is
proportional to the dimension/intensity of the bubbles. A color scale was used to determine the slope of the correlation. Blank squares indicate
no significant correlation. (B-H) Scatter plot of relationship between CSF PVALB levels and CTh of the most associated brain regions: (B) insula, (C)
cingulate gyrus, (D) hippocampus, (E) postcentral gyrus, (F) parahippocampal gyrus, (G) middle temporal gyrus, (H) superior frontal gyrus. Dots
represent the samples analyzed. R: Spearman correlation coefficient; P: P-value.
542 ª 2021 The Authors. Annals of Clinical and Translational Neurology published by Wiley Periodicals LLC on behalf of American Neurological Association
Parvalbumin Biomarker of Multiple Sclerosis Neurodegeneration R. Magliozzi et al.
with clinical and neuropsychological data, we found that
the CSF protein level of PVALB could represent a new
biomarker of GM damage, in particular of GM atrophy
and associated cognitive decline.
PVALB as a new biomarker of interneuronal
loss at early disease stage
Similar to other CSF biomarkers thought to reflect activ-
ity or damage associated with MS pathology and released
into the CSF,38 PVALB is most likely released into the
CSF as a consequence of interneuronal loss. Compared to
Nf-L, our results show that CSF PVALB levels correlate
better with cortical thinning and cognitive impairment
than Nf-L and also earlier, at the time of diagnosis. In
particular, CSF Nf-L levels were found to have a stronger
association with cortical lesion number at baseline com-
pared to the other examined MRI and clinical parameters.
On the contrary, PVALB CSF levels correlated, not only
with cortical lesion number but also with global and
regional cortical thinning, suggesting that it could repre-
sent a more specific marker of cortical neurodegenera-
tion-related atrophy.
These findings suggest that PVALB, by reflecting the
interneuron loss in the cortex, may represent primarily a
biomarker of specific cortical neurodegeneration that is
independent from cortical demyelination. Our results are
consistent with other studies suggesting that cortical thin-
ning is independent of demyelination (29; Wegner et al.,
2006; 14; 17). In particular, in line with previous data,29
we measured a similar reduction of PVALB gene expres-
sion and PVALB-positive neuronal loss both in GM
lesions and normal appearing GM of post-mortem MS
cases compared to controls. It has been suggested that in
chronic demyelination in the MS cortex, microglia may
be intimately associated with neuronal perikarya and
proximal dendrites and may mediate axonal degeneration
even in normal-appearing GM.16 The finding that high
levels of PVALB may be detected in MS patients at the
time of diagnosis and correlate with cortical thinning
more than cortical lesion load highly supports the
hypothesis that neurodegeneration might be independent
of cortical demyelination and can be estimated by MRI
analysis of cortical thickness changes in combination with
CSF assessment of PVALB levels. The fact that PVALB
Table 2. Correlations between global and regional CTh with both
CSF PVALB and Nf-L levels in MS patients.
CTh PVALB Nf-L
Global CTh 0.46 (P < 0.001) 0.23 (P = 0.024)
Insula 0.55 (P < 0.001) 0.24 (P = 0.012)
Cingulate gyrus 0.47 (P < 0.001) 0.27 (P = 0.005)
Hippocampus 0.46 (P < 0.001) n.s.
Postcentral gyrus 0.46 (P < 0.001) 0.24 (P = 0.010)
Parahippocampal gyrus 0.43 (P < 0.001) n.s.
Middle temporal gyrus 0.42 (P < 0.001) 0.24 (P = 0.014)
Superior frontal gyrus 0.42 (P < 0.001) n.s.
Calcarine cortex 0.42 (P < 0.001) n.s.
Precuneus 0.40 (P < 0.001) n.s.
Inferior temporal gyrus 0.40 (P < 0.001) n.s.
Supplementary motor cortex 0.39 (P < 0.001) n.s.
Cuneus 0.38 (P < 0.001) n.s.
Temporal pole 0.37 (P < 0.001) n.s.
Fusiform gyrus 0.37 (P < 0.001) n.s.
Middle frontal gyrus 0.35 (P < 0.001) 0.20 (P = 0.044)
Superior temporal gyrus 0.34 (P < 0.001) 0.20 (P = 0.032)
Superior occipital gyrus 0.29 (P = 0.002) n.s.
Middle occipital gyrus 0.27 (P = 0.006) 0.28 (P = 0.003)
Inferior occipital gyrus 0.25 (P = 0.009) n.s.
Rectus gyrus 0.22 (P = 0.021) n.s.
Precentral gyrus n.s. 0.26 (P = 0.007)
Spearman correlation coefficients and P-values (in brackets) are listed
in a decrescent order of association with PVALB.
Table 3. Results from the several regression models. For each regres-












Insula 0.63 *** 0.38 *
Cingulate gyrus 0.36 * 0.41 *
Hippocampus 0.31 *** / n.s.
Postcentral gyrus 0.22 *** / n.s.
Parahippoc. gyrus 0.30 ** / n.s.
Mid. Temporal gyrus 0.36 ** / n.s.
Sup. Frontal gyrus 0.22 *** / n.s.
Calcarine coretex 0.46 *** / n.s.
Precuneus 0.32 ** / n.s.
Inf. Temporal gyrus 0.20 0.07. / n.s.
Supplem. Motor
Cortex
0.30 *** / n.s.
Cuneus 0.23 * / n.s.
Temporal 0.33 *** / n.s.
Fusifrom gyrus 0.28 * / n.s.
Mid. Frontal gyrus 0.25 ** / n.s.
Sup. Temporal pole 0.21 *** / n.s.
Sup. Occipital gyrus 0.16 0.06 / n.s.
Mid. Occipital gyrus / n.s. 0.26 *
Inf. Occipital gyrus 0.19 0.07. / n.s.
Rectus gyrus 0.49 *** / n.s.
Precententral gyrus / n.s. 0.19 0.05
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and Nf-L levels in post-mortem CSF samples were sub-
stantially higher than in drug-na€ıve MS patients, may
imply that the level of interneuronal damage may be low
in early disease stages and may then slowly increase as
MS progresses. Assessment of PVALB CSF levels in fol-
low-up studies would possibly clarify whether this bio-
marker reflects the increase of neurodegeneration over-
time.
Loss of PVALB-positive interneurons is
associated with intrathecal inflammation
We found that the reduction of PVALB-positive neurons
is strictly associated with the density of activated micro-
glia in the same area and this is particularly elevated in
MS patients with meningeal lymphoid-like like structures.
In some of these patients, we previously identified a “sur-
face-in” gradient of microglial activation, higher in the
most external cortical layers close to the pial surface and
reduced close to the WM. The results of the present study
support the hypothesis that meningeal inflammation may
mediate and/or enhance cortical neurodegeneration possi-
bly by regulating/inducing subpial microglia activation.7
The fact that we found in-vivo CSF PVALB levels early in
the disease course, suggests that PVALB can be considered
as a biomarker of active cortical pathology, both in GM
lesions and in normal appearing GM.
The results from both post-mortem tissue and patient
studies confirm a key role for meningeal inflammation in
cortical damage and neurodegeneration. The finding of
higher loss of PVALB-positive neurons and the corre-
sponding increase in CSF levels in post-mortem MS cases
with meningeal lymphoid-like immune cell infiltrates, as
well as in the second independent MShigh population
with increased level of diffuse meningeal inflammation,
supports the hypothesis that inflammation, compartmen-
talized in the meninges, may contribute not only to GM
demyelination but also to neurodegeneration. These data
are strongly supported by the recent single-nucleus RNA
sequencing study in multiple cell lineages in MS lesions,
showing high vulnerability of upper-cortical-layer neurons
and reactive glia at the borders of subcortical MS lesions
associated with progression in MS.18
PVALB represents a biomarker of cortical
damage in early MS
In our study, we found a moderate significant correlation
between PVALB concentration in the CSF and the reduc-
tion of cortical thickness, but not with WM demyelina-
tion. Our analyses demonstrated that CSF-PVALB
variable may play a key role in explaining the variance of
Global CTh. This finding was particularly evident in cer-
tain cortical regions, such as insula, cingulate gyrus, hip-
pocampus, postcentral gyrus, parahippocampal gyrus,
middle temporal gyrus, and superior frontal gyrus, which
were all previously identified by both neuropathological
and MRI studies.7,31,39–41 as severely affected by cortical
pathology. These cortical regions, similar to the motor
cortex, in which a reduction of PVALB gene expression
and GABA-ergic interneurons have been observed, seem
to be the most susceptible to neurodegeneration at least
in the early stage of the disease. Previous studies hypothe-
sized that the effect of meningeal inflammation was stron-
ger in those regions of the cortex with deep invaginations
and low CSF flow, such as insula and cingulate gyrus.41,42
In our study, these regions seemed to be highly correlated
with the CSF PVALB values supporting, from an MRI
point of view, the association between meningeal inflam-
mation and neurodegeneration.
Figure 5. Correlations between cognitive impairment and global cortical thickness and with CSF PVALB and NF-L levels in MS patients. (A)
Boxplot representing the comparison of PVALB levels among the MS groups characterized by different levels of cognitive impairment. (B) Boxplot
representing the comparison of Nf-L level among the MS groups characterized by different levels of cognitive impairment. Boxplots show the
medians and the two hinges. Dots represent the individual samples analyzed. *P < 0.05. CTh: cortical thickness; CN: cognitively normal MS
patients; mCI: MS patients with mild cognitive impairment; sCI: MS patients with severe cognitive impairment.
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PVALB as potential prognostic biomarker of
more severe disease outcome in progressive
MS
The post-mortem MS cases with an increased degree of
meningeal inflammation and cortical pathology were
characterized by a more severe and rapid disease progres-
sion15 and by the most extensive interneuronal loss
together with high CSF levels of PVALB. The negative
correlations identified between CSF PVALB levels and
both age of onset and age of death of these post-mortem
cases suggest an inflammation-driven neurodegeneration
mechanism that possibly is linked to early and more sev-
ere disease (early age of death). In the early relapsing
remitting phase of the na€ıve MS patients, we did not find
significant correlations between PVALB CSF levels and
clinical parameters, such as EDSS. This is possibly due to
either to the cortical plasticity, that allows good compen-
satory mechanisms and that accumulation of neurodegen-
eration plays a role mainly in the progressive disease
phase,43 or to the prevalent involvement of white matter
lesions in the initial disease outcome.
PVALB, a biomarker associated with
cognitive dysfunction
The high PVALB CSF level observed in patients with sev-
ere CI suggests that PVALB could be a valuable biomar-
ker of cognitive dysfunction related to cortical pathology
since the early phase of the disease. This is in line with
previous studies showing a relationship between CI and
GM damage rather than with WM damage.44 We also
observed that PVALB is more correlated with CTh respect
to CLs, thus suggesting that CI is more associated with
diffuse GM neuronal and interneuronal loss than focal
cortical GM damage, which seems to be mainly captured
by the Nf-L CSF level. Although CSF Nf-L might reflect
CI in MS patients even in the earliest phases of the dis-
ease,45–47 it should not be considered as a biomarker
specific for CI, since its levels in the CSF increase as an
expression of axonal damage, which in turn may be the
basis of the involvement of functional systems other than
the cognitive one.43 This observation can also contribute
to explain why PVALB is more associated with cognitive
rather than physical (measured by EDSS) disability. The
present results may suggest that PVALB might be more
sensitive than Nf-L in detecting CI since the earliest phase
of the disease because its association with both neuronal
and interneuronal loss in the GM. Extending this study to
a larger and independent MS population, and integrating
a long follow-up period of combined clinical, radiological,
and neuropsychological analysis, could reveal the role of
PVALB as a potential better predictive biomarker, with
respect to Nf-L, either of cognitive decline or of worst
brain atrophy in the long-term disease course.
Conclusions
By combining a molecular neuropathology, MRI, clinical,
and neuropsychological approach, we have shown that
CSF PVALB levels represent a new potential biomarker of
interneuron loss in the cortex of MS patients, both at
time of diagnosis and, increasing with progression, at
time of death. In particular, this biomarker is able to
reflect early alterations in cortical thickness and cognitive
impairment, not revealed from assessment of CSF Nf-L
levels and may, therefore, be useful to more efficiently
recognize MS patients that present with early signs of
neurodegeneration and related cognitive decline enabling
treatment with specific combinations of neuroprotective
and immunomodulatory treatments.
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